These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27623122)

  • 21. Bipolar depression: a new role for atypical antipsychotics?
    Keck PE
    Bipolar Disord; 2005; 7 Suppl 4():34-40. PubMed ID: 15948765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review.
    Drevets WC; Zarate CA; Furey ML
    Biol Psychiatry; 2013 Jun; 73(12):1156-63. PubMed ID: 23200525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study.
    Suppes T; Silva R; Cucchiaro J; Mao Y; Targum S; Streicher C; Pikalov A; Loebel A
    Am J Psychiatry; 2016 Apr; 173(4):400-7. PubMed ID: 26552942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
    Kaneriya SH; Robbins-Welty GA; Smagula SF; Karp JF; Butters MA; Lenze EJ; Mulsant BH; Blumberger D; Anderson SJ; Dew MA; Lotrich F; Aizenstein HJ; Diniz BS; Reynolds CF
    JAMA Psychiatry; 2016 Apr; 73(4):329-36. PubMed ID: 26963689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension.
    Goldberg JF; Ng-Mak D; Siu C; Chuang CC; Rajagopalan K; Loebel A
    CNS Spectr; 2017 Apr; 22(2):220-227. PubMed ID: 28264739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials.
    Arbaizar B; Dierssen-Sotos T; Gómez-Acebo I; Llorca J
    Gen Hosp Psychiatry; 2009; 31(5):478-83. PubMed ID: 19703642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine.
    Furey ML; Drevets WC; Szczepanik J; Khanna A; Nugent A; Zarate CA
    Int J Neuropsychopharmacol; 2015 Mar; 18(8):. PubMed ID: 25820840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of scopolamine compared to placebo in individuals with bipolar disorder who are experiencing a depressive episode (SCOPE-BD): study protocol for a randomised double-blind placebo-controlled trial.
    Miravalles C; Kane R; McMahon E; McDonald C; Cannon DM; Hallahan B
    Trials; 2022 Apr; 23(1):339. PubMed ID: 35461262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis.
    Swann AC; Fava M; Tsai J; Mao Y; Pikalov A; Loebel A
    CNS Spectr; 2017 Apr; 22(2):228-235. PubMed ID: 28300012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
    Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
    Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression.
    Gebara MA; DiNapoli EA; Kasckow J; Karp JF; Blumberger DM; Lenze EJ; Mulsant BH; Reynolds CF
    Int J Geriatr Psychiatry; 2018 Feb; 33(2):e330-e335. PubMed ID: 28975710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Randomized Controlled Trial of Intravenous Scopolamine Versus Active-Placebo Glycopyrrolate in Patients With Major Depressive Disorder.
    Chen JCC; Sumner RL; Naga VK; Hoeh N; Ayeni HA; Singh V; Wilson A; Campbell D; Sundram F; Muthukumaraswamy SD
    J Clin Psychiatry; 2022 Aug; 83(5):. PubMed ID: 35980261
    [No Abstract]   [Full Text] [Related]  

  • 34. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression.
    Goldberg JF; Burdick KE; Endick CJ
    Am J Psychiatry; 2004 Mar; 161(3):564-6. PubMed ID: 14992985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
    Rong C; Park C; Rosenblat JD; Subramaniapillai M; Zuckerman H; Fus D; Lee YL; Pan Z; Brietzke E; Mansur RB; Cha DS; Lui LMW; McIntyre RS
    Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29673146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression.
    Dunn RT; Stan VA; Chriki LS; Filkowski MM; Ghaemi SN
    J Affect Disord; 2008 Sep; 110(1-2):70-4. PubMed ID: 18272230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pramipexole for stage 2 treatment-resistant major depression: an open study.
    Inoue T; Kitaichi Y; Masui T; Nakagawa S; Boku S; Tanaka T; Suzuki K; Nakato Y; Usui R; Koyama T
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1446-9. PubMed ID: 20708060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study.
    Angst J; Azorin JM; Bowden CL; Perugi G; Vieta E; Gamma A; Young AH;
    Arch Gen Psychiatry; 2011 Aug; 68(8):791-8. PubMed ID: 21810644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
    Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
    J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.